Answers are grounded in this paper and cite their sources.
Finds apolipoprotein A1 does not effectively distinguish Alzheimer's from other dementias, suggesting limitations in its use as a biomarker.
Apolipoprotein A1 (ApoA1) is the major protein component of the high-density lipoprotein and involved in cholesterol transport. Disruption of cholesterol homeostasis has been identified as a contributing factor for Alzheimer's disease (AD). Moreover, polymorphisms of ApoA1 have been associated with higher risk of disease onset and cognitive decline. Therefore, ApoA1 has been suggested as a biomarker in AD. Here, we tested a small cohort of AD and non-AD dementia patients and measured levels of ApoA1 in cerebrospinal fluid. Our results indicate that ApoA1 might not be applicable to distinguish AD from other forms of dementia.
No takes yet. Share an insight, caveat, or question.
Stoye et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: